Ionis Pharmaceuticals IONS Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's cash, cash equivalents, and marketable securities?
- Ionis Pharmaceuticals (IONS) reported cash, cash equivalents, and marketable securities of $1.03B in Q1 2026.
- How has Ionis Pharmaceuticals's cash, cash equivalents, and marketable securities changed year-over-year?
- Ionis Pharmaceuticals's cash, cash equivalents, and marketable securities increased by 28.1% year-over-year, from $806.7M to $1.03B.
- What does cash, cash equivalents, and marketable securities mean?
- The total amount of cash and easily sellable investments the company owns.
- How do you interpret cash, cash equivalents, and marketable securities?
- An increase indicates a stronger liquidity position and greater ability to fund long-term R&D pipelines without immediate dilution.
- How does cash, cash equivalents, and marketable securities compare across companies?
- A primary metric for assessing financial health in pre-profit or growth-stage pharmaceutical companies.